Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Estradiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Mayne Pharma
Deal Size : $225.7 million
Deal Type : Licensing Agreement
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
Details : Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
Product Name : Imvexxy
Product Type : Hormone
Upfront Cash : $140.0 million
March 01, 2023
Lead Product(s) : Estradiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Mayne Pharma
Deal Size : $225.7 million
Deal Type : Licensing Agreement
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The sNDA included minor revisions to Annovera (segesterone acetate) in vitro release testing specification that allowed for normal manufacturing variability, was approved by the FDA in August 2018 as the only long-lasting, reversible, procedure-free birt...
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estradiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Mayne Pharma
Deal Size : $225.7 million
Deal Type : Agreement
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
Details : Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
Product Name : Imvexxy
Product Type : Hormone
Upfront Cash : $140.0 million
April 12, 2022
Lead Product(s) : Estradiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Mayne Pharma
Deal Size : $225.7 million
Deal Type : Agreement
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Rubric Capital Management
Deal Size : $15.0 million
Deal Type : Financing
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
Details : TherapeuticsMD has three growing assets whose value has been enhanced by the recent approval of both Annovera’s (segesterone acetate) supplemental NDA and lower-dose Bijuva, as well as the increasing relevance of convenient and safe contraceptive optio...
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
January 08, 2022
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Rubric Capital Management
Deal Size : $15.0 million
Deal Type : Financing
Lead Product(s) : Estradiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Cantor Fitzgerald
Deal Size : $110.0 million
Deal Type : Public Offering
TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock
Details : TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products, IMVEXXY® (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual acti...
Product Name : Imvexxy
Product Type : Hormone
Upfront Cash : Undisclosed
November 02, 2021
Lead Product(s) : Estradiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Cantor Fitzgerald
Deal Size : $110.0 million
Deal Type : Public Offering
Lead Product(s) : Estradiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Cantor Fitzgerald
Deal Size : $30.0 million
Deal Type : Public Offering
TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock
Details : TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products which includes IMVEXXY®, BIJUVA® and ANNOVERA®, and for working capital and general corporate purposes.
Product Name : Imvexxy
Product Type : Hormone
Upfront Cash : Undisclosed
October 11, 2020
Lead Product(s) : Estradiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Cantor Fitzgerald
Deal Size : $30.0 million
Deal Type : Public Offering
Lead Product(s) : Estradiol,Progesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Knight Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
Details : BIJUVA is a once-daily combination of estradiol and progesterone in a single oral capsule that will be available in two strengths in Canada indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an in...
Product Name : Bijuva
Product Type : Hormone
Upfront Cash : Inapplicable
September 21, 2020
Lead Product(s) : Estradiol,Progesterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Knight Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Nurx
Deal Size : Undisclosed
Deal Type : Agreement
TherapeuticsMD and Nurx Expand Access to ANNOVERA®
Details : The agreement is aimed at expanding access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual birth control ring. ANNOVERA is the first FDA-approved long-lasting birth control method that does not require...
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
July 15, 2020
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Nurx
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol,Itraconazole,Rifampicin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Annoveraâ„¢ Drug-Drug Interaction Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
February 28, 2020
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol,Itraconazole,Rifampicin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol,Tampon
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
February 17, 2020
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol,Tampon
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable